# PTOV1

## Overview
PTOV1, or Prostate Tumor Overexpressed 1, is a gene that encodes the PTOV1 extended AT-hook containing adaptor protein, which plays a crucial role in cellular processes such as cell cycle regulation and proliferation. The PTOV1 protein is characterized by its unique structure, including two homologous domains and an extended AT-hook domain, which facilitate its interactions with nucleic acids and other proteins. Functionally, PTOV1 acts as a transcriptional regulator, influencing the expression of genes involved in cell proliferation and cancer progression. It is notably involved in the regulation of the cell cycle, promoting the transition into the S phase, and is implicated in various cancers, including prostate, breast, and ovarian cancers, where its overexpression is associated with poor prognosis and aggressive tumor characteristics (Lei2014Overexpression; Santamaría2003PTOV1; Shen2021PTOV1). PTOV1's interactions with proteins such as 14-3-3 and components of the Notch repressor complex further underscore its role in oncogenic pathways, making it a potential target for therapeutic intervention (Pennington2021SGK2; Cánovas2016The).

## Structure
The PTOV1 protein, also known as Prostate tumor-overexpressed gene 1 protein, is characterized by its unique molecular structure, which includes two homologous regions known as the A and B domains. The A domain spans amino acids 88-234, while the B domain covers amino acids 253-336. These domains are unusual in sequence but share similarities with a domain found in the Mediator of RNA polymerase II transcription subunit 25 (MED25) (Pennington2021SGK2).

At the N-terminus, PTOV1 features a 43-amino acid stretch forming a putative nucleic acid-binding extended AT-hook (eAT hook) domain, which has an affinity for RNA. This domain is crucial for the protein's localization, as its deletion leads to PTOV1 accumulation in the nucleus (Pennington2021SGK2).

PTOV1 undergoes post-translational modifications, notably phosphorylation at serine residues S36 and S53, which are essential for its interaction with the 14-3-3 protein family. This phosphorylation is mediated by the kinase SGK2 and is critical for maintaining PTOV1 in the cytosol, preventing its degradation (Pennington2021SGK2).

The protein also contains putative nuclear localization sequences within each of its domains, facilitating its nucleo-cytoplasmic shuttling in a cell cycle-dependent manner (Pennington2021SGK2).

## Function
PTOV1, or Prostate Tumor Overexpressed 1, is a protein that plays a significant role in cell cycle regulation and proliferation. It is primarily involved in promoting the transition of cells into the S phase of the cell cycle, which is crucial for DNA replication and cell division. PTOV1 shuttles between the cytoplasm and the nucleus in a cell-cycle-dependent manner. During quiescence, PTOV1 is located in the cytoplasm, but it translocates to the nucleus as cells enter the S phase, where it remains until mitosis (Santamaría2003PTOV1).

In the nucleus, PTOV1 acts as a transcriptional regulator, influencing the expression of genes involved in cell proliferation. It is associated with increased levels of cyclin D1, a protein that promotes cell cycle progression, and is linked to a higher proliferative index in cancer cells (Santamaría2003PTOV1). PTOV1's activity is regulated by interactions with other proteins, such as 14-3-3, which sequesters it in the cytosol to prevent premature nuclear entry and inappropriate gene expression (Pennington2021SGK2). This regulation is crucial for maintaining proper cell cycle control and ensuring orderly cell division.

## Clinical Significance
PTOV1 (Prostate Tumor Overexpressed 1) is implicated in the progression and prognosis of several cancers due to its overexpression and interaction with various cellular pathways. In breast cancer, PTOV1 is frequently overexpressed, correlating with aggressive clinicopathological features and poor prognosis. High PTOV1 expression is associated with shorter survival times, making it a potential independent prognostic marker (Lei2014Overexpression).

In prostate cancer, PTOV1 overexpression is linked to increased tumor aggressiveness and poor survival outcomes. It is associated with the expression of genes like ALDH1A1 and CCNG2, which are involved in cancer progression and metastasis (Maggio2019A). PTOV1 also interacts with the Notch signaling pathway, repressing target genes such as HES1 and HEY1, which contributes to its pro-oncogenic role in prostate cancer (Alaña2014Prostate).

In ovarian cancer, PTOV1 overexpression is linked to chemotherapy resistance, particularly to cisplatin, through the activation of the NF-kB pathway. This resistance is associated with poor patient outcomes, highlighting PTOV1 as a potential target for therapeutic intervention (Shen2021PTOV1). PTOV1's role in various cancers underscores its clinical significance as a biomarker and potential therapeutic target.

## Interactions
PTOV1 interacts with several proteins and nucleic acids, playing a significant role in cancer progression. It binds to specific promoter sequences of genes such as ALDH1A1 and CCNG2, facilitated by a novel DNA-binding motif within its PTOV-A domain, which resembles AT-hook motifs (Maggio2019A). PTOV1 also interacts with RACK1 on the 40S ribosomal subunit, indicating a role in translation initiation. This interaction is necessary for PTOV1's association with ribosomes, as shown by its failure to co-sediment with the 40S subunit in RACK1 knockdown cells (Cánovas2016The).

PTOV1's interaction with the 14-3-3 protein is mediated by SGK2-mediated phosphorylation, which regulates its localization and stability by preventing its binding to the E3 ubiquitin ligase HUWE1, thus avoiding degradation (Pennington2021SGK2). PTOV1 also interacts with components of the Notch repressor complex, such as SMRT, RBP-Jκ, NCoR, HDAC1, and HDAC4, to repress transcription of Notch downstream targets like HES1 and HEY1 (Cánovas2016The; Alaña2014Prostate).

In addition, PTOV1 interacts with Flotillin-1 in lipid rafts and the nucleus, which is crucial for cell proliferation in prostate cancer cells (Cánovas2016The). These interactions highlight PTOV1's involvement in transcriptional regulation and translation, contributing to its role in cancer progression.


## References


[1. (Santamaría2003PTOV1) Anna Santamaría, Pedro L. Fernández, Xavier Farré, Patricia Benedit, Jaume Reventós, Juan Morote, Rosanna Paciucci, and Timothy M. Thomson. Ptov-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the s phase of the cell division cycle. The American Journal of Pathology, 162(3):897–905, March 2003. URL: http://dx.doi.org/10.1016/s0002-9440(10)63885-0, doi:10.1016/s0002-9440(10)63885-0. This article has 47 citations.](https://doi.org/10.1016/s0002-9440(10)63885-0)

[2. (Cánovas2016The) Verónica Cánovas, Matilde Lleonart, Juan Morote, and Rosanna Paciucci. The role of prostate tumor overexpressed 1 in cancer progression. Oncotarget, 8(7):12451–12471, December 2016. URL: http://dx.doi.org/10.18632/oncotarget.14104, doi:10.18632/oncotarget.14104. This article has 11 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.14104)

[3. (Lei2014Overexpression) Fangyong Lei, Longjuan Zhang, Xinghua Li, Xi Lin, Shu Wu, Fengyan Li, and Junling Liu. Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer. BMC Cancer, June 2014. URL: http://dx.doi.org/10.1186/1471-2407-14-457, doi:10.1186/1471-2407-14-457. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-14-457)

[4. (Maggio2019A) Valentina Maggio, Verónica Cánovas, Alex J. Félix, Valentí Gómez, Inés de Torres, María Eugenia Semidey, Juan Morote, Verónique Noé, Carlos J. Ciudad, and Rosanna Paciucci. A novel dna-binding motif in prostate tumor overexpressed-1 (ptov1) required for the expression of aldh1a1 and ccng2 in cancer cells. Cancer Letters, 452:158–167, June 2019. URL: http://dx.doi.org/10.1016/j.canlet.2019.03.019, doi:10.1016/j.canlet.2019.03.019. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2019.03.019)

[5. (Pennington2021SGK2) Katie L. Pennington, Colten M. McEwan, James Woods, Colin M. Muir, A.G. Pramoda Sahankumari, Riley Eastmond, Eranga R. Balasooriya, Christina M. Egbert, Sandeep Kaur, Tyler Heaton, Katherine K. McCormack, Stephen R. Piccolo, Manabu Kurokawa, and Joshua L. Andersen. Sgk2, 14-3-3, and huwe1 cooperate to control the localization, stability, and function of the oncoprotein ptov1. Molecular Cancer Research, 20(2):231–243, October 2021. URL: http://dx.doi.org/10.1158/1541-7786.mcr-20-1076, doi:10.1158/1541-7786.mcr-20-1076. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1158/1541-7786.mcr-20-1076)

[6. (Shen2021PTOV1) Hongwei Shen, Bing Liao, Zhiyong Wan, Yunhe Zhao, Zeshan You, Jun Liu, Jin Lan, and Shanyang He. Ptov1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa b pathway in ovarian cancer. Molecular Therapy - Oncolytics, 20:499–507, March 2021. URL: http://dx.doi.org/10.1016/j.omto.2021.02.008, doi:10.1016/j.omto.2021.02.008. This article has 7 citations.](https://doi.org/10.1016/j.omto.2021.02.008)

[7. (Alaña2014Prostate) Lide Alaña, Marta Sesé, Verónica Cánovas, Yolanda Punyal, Yolanda Fernández, Ibane Abasolo, Inés de Torres, Cristina Ruiz, Lluís Espinosa, Anna Bigas, Santiago Ramón y Cajal, Pedro L Fernández, Florenci Serras, Montserrat Corominas, Timothy M Thomson, and Rosanna Paciucci. Prostate tumor overexpressed-1 (ptov1) down-regulates hes1 and hey1 notch targets genes and promotes prostate cancer progression. Molecular Cancer, March 2014. URL: http://dx.doi.org/10.1186/1476-4598-13-74, doi:10.1186/1476-4598-13-74. This article has 26 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-13-74)